Suppr超能文献

补心软脉颗粒通过调控miR-542-3p/GABARAP信号通路减轻冠心病患者心绞痛

Granule of BU-XIN RUAN-MAI Attenuates the Patients' Angina Pectoris of Coronary Heart Disease via Regulating miR-542-3p/GABARAP Signaling.

作者信息

Yan Dong, Zhao Li-Li, Yue Bo-Wen, Qian Hui, Zhang Zi-Han, Wang Ning, Yan Shi-Hai, Qian Yu-Liang

机构信息

Department of Pharmacology, Affiliated Hospital of Nanjing University of TCM, Nanjing, China.

Nanjing University of TCM, Nanjing, China.

出版信息

Evid Based Complement Alternat Med. 2019 Dec 26;2019:1808419. doi: 10.1155/2019/1808419. eCollection 2019.

Abstract

OBJECTIVE

Coronary heart disease (CHD) has been regarded as a serious and common disease in the modern society. This study aims to investigate the effect of Granule of BU-XIN RUAN-MAI (BXRM) on angina pectoris of coronary heart disease and to explore the molecular mechanisms underlying Granule of BU-XIN RUAN-MAI-mediated protective activity against this disease.

METHODS

The effects of Granule of BU-XIN RUAN-MAI on clinical symptoms of patients' angina were indicated by hemorheology indicators including high shear of blood viscosity, low shear of blood viscosity, plasma viscosity, erythrocyte rigidity index, D-D dimer, fibrinogen content, and lipid content. The effects of Granule of BU-XIN RUAN-MAI on isoprenaline-induced myocardial cell injury were determined by conducting H&E staining and by performing ELISA to examine the serum content of MDA, SOD, Na/K-ATPase, cAMP, and the content of inflammatory factors in isoprenaline-induced rats. Meanwhile, western blot and real time PCR were used to determine the expression of genes involved in oxidation and energy metabolism, and real time PCR was also used for determination of miR-542-3p expression. Luciferase reporter assay was conducted to test the binding sites of miR-542-3p on GABARAP 3'UTR. The chemical compositions of Granule of BU-XIN RUAN-MAI were determined by liquid LC-QTOF-MS.

RESULTS

Granule of BU-XIN RUAN-MAI significantly attenuated the clinical symptoms of patients' angina by improving the patients' heart rate and by decreasing the level of hemorheology indicators and also by reducing the serum content of TC, TG, LDL, and elevated HDL content. H&E staining demonstrated that Granule of BU-XIN RUAN-MAI ameliorated the myocardial ischemia in a dose-dependent manner. Besides, Granule of BU-XIN RUAN-MAI downregulated serum MDA content and upregulated the content of SOD, Na/K-ATPase, and cAMP in isoprenaline-induced rats. Granule of BU-XIN RUAN-MAI significantly improved oxidation stress by increasing PPAR expression, and it inhibited inflammation by downregulating expression and contents of IL-6, IL-1, and TNF-. Then, Granule of BU-XIN RUAN-MAI-containing serum increased the SOD content, and reduced the MDA content in angiotensin II-stimulated HUVEC cells. The granule of BU-XIN RUAN-MAI-containing serum obviously downregulated protein expressions of P40phox, P47phox, and P67phox in plasma membrane, and it significantly increased protein levels of P40phox, P47phox, and P67phox in the cytoplasm of HUVEC cells. Furthermore, GABARAP was reduced in heart tissues of ISO-induced rats and in angiotensin II-stimulated cell lines, and GABARAP was required for the inhibitory activity of Granule of BU-XIN RUAN-MAI on oxidation and inflammation and . GABARAP could be upregulated by Granule of BU-XIN RUAN-MAI by inhibiting the expression of miR-542-3p, which may significantly enhance oxidation and inflammation by targeting GABARAP in cardiomyocytes. Moreover, the silencing of GABARAP could obviously reverse the granule of BU-XIN RUAN-MAI-mediated protective activity against coronary heart disease, and interfering GABARAP expression also could partly block the anti-miR-542-3p-controlled oxidation and inflammation in cardiomyocytes. Besides, , , and were the main compounds of granules of BU-XIN RUAN-MAI.

CONCLUSION

Granule of BU-XIN RUAN-MAI is an excellent prescription for treatment of coronary heart disease by suppressing inflammation and NAPDH-mediated oxidative stress. The miR-542-3p/GABARAP axis is required for Granule of BU-XIN RUAN-MAI, exhibiting its protective activity against the pectoris of coronary heart disease.

摘要

目的

冠心病(CHD)在现代社会中被视为一种严重且常见的疾病。本研究旨在探讨补心软脉颗粒(BXRM)对冠心病心绞痛的影响,并探究补心软脉颗粒介导的针对该疾病的保护活性的分子机制。

方法

通过包括高切变率全血黏度、低切变率全血黏度、血浆黏度、红细胞刚性指数、D - 二聚体、纤维蛋白原含量和血脂含量等血液流变学指标来表明补心软脉颗粒对患者心绞痛临床症状的影响。通过苏木精 - 伊红(H&E)染色以及酶联免疫吸附测定(ELISA)检测异丙肾上腺素诱导的大鼠血清中丙二醛(MDA)、超氧化物歧化酶(SOD)、钠钾 - 三磷酸腺苷酶(Na/K - ATPase)、环磷腺苷(cAMP)的含量以及炎症因子的含量,来确定补心软脉颗粒对异丙肾上腺素诱导的心肌细胞损伤的影响。同时,采用蛋白质免疫印迹法(western blot)和实时定量聚合酶链反应(real time PCR)来测定参与氧化和能量代谢的基因表达,实时定量聚合酶链反应还用于测定miR - 542 - 3p的表达。进行荧光素酶报告基因检测以测试miR - 542 - 3p在GABARAP 3'非翻译区(UTR)的结合位点。通过液相色谱 - 四极杆飞行时间质谱(LC - QTOF - MS)测定补心软脉颗粒的化学成分。

结果

补心软脉颗粒通过改善患者心率、降低血液流变学指标水平以及降低血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)水平并提高高密度脂蛋白(HDL)水平,显著减轻了患者心绞痛的临床症状。H&E染色表明补心软脉颗粒以剂量依赖的方式改善心肌缺血。此外,补心软脉颗粒下调了异丙肾上腺素诱导的大鼠血清MDA含量,并上调了SOD、Na/K - ATPase和cAMP的含量。补心软脉颗粒通过增加过氧化物酶体增殖物激活受体(PPAR)表达显著改善氧化应激,并通过下调白细胞介素 - 6(IL - 6)、白细胞介素 - 1(IL - 1)和肿瘤坏死因子 -α(TNF -α)的表达和含量来抑制炎症。然后,含补心软脉颗粒血清增加了血管紧张素II刺激的人脐静脉内皮细胞(HUVEC)中的SOD含量,并降低了MDA含量。含补心软脉颗粒血清明显下调了HUVEC细胞膜中P40phox、P47phox和P67phox的蛋白表达,并显著增加了HUVEC细胞质中P40phox、P47phox和P67phox的蛋白水平。此外,在异丙肾上腺素诱导的大鼠心脏组织和血管紧张素II刺激的细胞系中,GABARAP表达降低,并且GABARAP是补心软脉颗粒对氧化和炎症抑制活性所必需的。补心软脉颗粒可通过抑制miR - 542 - 3p的表达上调GABARAP,miR - 542 - 3p可能通过靶向心肌细胞中的GABARAP显著增强氧化和炎症。此外,沉默GABARAP可明显逆转补心软脉颗粒介导的对冠心病的保护活性,干扰GABARAP表达也可部分阻断抗miR - 542 - 3p控制的心肌细胞氧化和炎症。此外,[具体化合物名称1]、[具体化合物名称2]和[具体化合物名称3]是补心软脉颗粒的主要成分。

结论

补心软脉颗粒是通过抑制炎症和烟酰胺腺嘌呤二核苷酸磷酸(NAPDH)介导的氧化应激来治疗冠心病的优良方剂。miR - 542 - 3p/GABARAP轴对于补心软脉颗粒发挥其对冠心病心绞痛的保护活性是必需的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ca/6948311/0f5403704be5/ECAM2019-1808419.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验